ICH Q10 Moves to Final Stage: International Adoption

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The steering committee of the International Conference on Harmonization and its expert working groups adopted Quality Guideline Q10 "Quality Systems" last week at a meeting in Portland, Oregon.

Portland, OR (June 5)-The steering committee of the International Conference on Harmonization and its expert working groups adopted Quality Guideline Q10 “Quality Systems” last week at a meeting in Portland, Oregon. The adoption represents the final stage of the harmonization process, which means that all parties to ICH (the US, Europe, and Japan) have reached scientific consensus on the technical issues of the guideline’s text and agreed to fully implement the guideline through their individual regulatory bodies.

Q10 was in Step 3 (the consultation and comment period) from May 2007 until last week, the ICH parties finalized the guideline’s concept in late 2005.

Q10 incorporates the concepts behind ICH Q8 “Pharmaceutical Development” and ICH Q9 “Quality Risk Management” by providing a model for a pharmaceutical quality system that can be implemented throughout a product life cycle. Q10 is meant to complement and add to current good manufacturing practices but, as a guideline, is not enforceable. The overall goal, according to the Q10 business plan, is to facilitate innovation and continual improvement and strengthen the link between pharmaceutical development and manufacturing activities.

Pharmaceutical Technology and SGS will host a web seminar titled “Quality Systems in the Global Marketplace” on June 12. Some of the panelists in the webcast participated in the ICH meeting in Portland last week and will be answering questions from industry. Log on to the registration page to watch the webcast live or visit pharmtech.com later to watch it online.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes